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Abstract
Introduction Pre-diabetes is a high-risk state for the
development of type 2 diabetes mellitus (T2DM) and
cardiovascular disease. Regression to normoglycaemia,
even if transient, significantly reduces the risk of
developing T2DM. The primary aim of this mixed-methods
study is to determine if there are clinically relevant
differences among those with pre-diabetes and excess
weight who regress to normoglycaemia, those who have
persistent pre-diabetes and those who progress to T2DM
following participation in a 6-month primary care nurse-
delivered pre-diabetes dietary intervention. Incidence of
T2DM at 2 years will be examined.
Methods and analysis Four hundred participants
with pre-diabetes (New Zealand definition glycated
haemoglobin 41–49 mmol/mol) and a body mass index
>25 kg/m2 will be recruited through eight primary care
practices in Hawke’s Bay, New Zealand. Trained primary
care nurses will deliver a 6-month structured dietary
intervention, followed by quarterly reviews for 18 months
post-intervention. Clinical data, data on lifestyle factors
and health-related quality of life (HR-QoL) and blood
samples will be collected at baseline, 6 months, 12
months and 24 months. Sixty participants purposefully
selected will complete a semi-structured interview
following the 6-month intervention. Poisson regression
with robust standard errors and clustered by practice will
be used to identify predictors of regression or progression
at 6 months, and risk factors for developing T2DM at
2 years. Qualitative data will be analysed thematically.
Changes in HR-QoL will be described and potential cost
savings will be estimated from a funder’s perspective at 2
years.
Ethics and dissemination This study was approved by
the Northern A Health and Disability Ethics Committee,
New Zealand (Ethics Reference: 17/NTA/24). Study
results will be presented to participants, published
in peer-reviewed journals and presented at relevant
conferences.
Trial registration number ACTRN12617000591358;
Pre-results.

Strengths and limitations of this study
►► This mixed-methods study follows a pragmatic non-

randomised pilot study which showed that a primary
care nurse-delivered 6-month dietary intervention
for people with pre-diabetes and body mass index
>25 kg/m2 was feasible in a primary care setting,
and weight loss was achieved in the intervention
group.
►► The study is set in a geographical region where
approximately 21% of the population is Māori, the
indigenous peoples of New Zealand, who have high
rates of pre-diabetes and type 2 diabetes mellitus.
►► Following the 6-month dietary intervention, participants will be reviewed every 3 months by primary
care nurses for 18 months.
►► A possible limitation is that the study is taking place
in a real-world setting, and health sector changes
influencing the primary care environment may influence the study outcomes.
►► This study is limited as it will not include a control
group.

Introduction
The prevalence of diabetes and concomitant costs continue to increase.1–4 Diabetes
now affects an estimated 8.8% of adults
globally.5 Pre-diabetes, a condition in which
blood glucose levels are higher than normal,
but not high enough to be classified as
diabetes, is more common, affecting as many
as 30%–50% of some adult populations.6–9
Without treatment, about 5%–10% of those
diabetes will progress to type 2
with pre-
diabetes mellitus (T2DM) annually, and most
will eventually develop T2DM.10 11 Lifestyle
modification and weight loss can prevent or
delay progression,12–18 with the overall risk
being approximately halved.19 Medication
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has also been shown to prevent T2DM in people with pre-
diabetes enrolled in clinical trials.12 19–21
Implementing diabetes prevention lifestyle interventions in
primary care: the challenges
Implementing diabetes prevention lifestyle clinical trial
evidence into real-world settings is challenging, particularly in primary care settings,22–24 where those with
pre-diabetes are typically a more heterogeneous group
compared with those participating in clinical trials.25
Further, the cost of delivering lifestyle interventions in
primary care can be a barrier.26 The Diabetes Prevention Program (DPP) lifestyle intervention costs US$1399
per participant in the first year.27 A significant proportion of this cost was specialist lifestyle intervention staff,
who are often employed in diabetes prevention lifestyle
programmes, irrespective of the setting.12–17 28–35 Few
studies have specifically employed primary care nurses to
deliver lifestyle advice,36–39 although dietary advice given
by an appropriately trained nurse can be as effective as
that given by a dietitian in the primary care setting,38 and
is potentially more sustainable and cost-effective.40
Furthermore, as pre-diabetes increases the risk of not
only T2DM, but also cardiovascular disease,6 11 41 and the
microvascular complications associated with diabetes,6 42
the goal of pre-diabetes screening and treatment should
arguably be regression to normoglycaemia.11 21 43 Even
if transient, regression to normoglycaemia is associated
with a significantly reduced risk of developing T2DM,
independent of whether this occurs spontaneously or
in response to lifestyle advice or metformin therapy.44
Greater insulin secretion, lower baseline glucose concentrations, younger age, weight loss and intensive lifestyle
modification predict restoration of normoglycaemia,45–47
but other factors such as sociocultural, economic and
health service delivery, which have not been previously
examined, may also be important.
Pre-diabetes lifestyle interventions have been implemented in
primary care
The primary care-based Pre-diabetes Intervention Package
(PIP) is a feasible primary care nurse-delivered 6-month
pre-diabetes lifestyle intervention with a focus on diet,
sociocultural context and goal setting, for overweight
and obese patients with pre-diabetes.48 In this pragmatic
mixed-methods non-randomised pilot study conducted in
the Hawke’s Bay region, New Zealand (NZ), intervention
implementation fidelity was high and after adjustment,
the intervention group lost a mean 1.3 kg more than the
control group (p<0.0.001). The mean glycated haemoglobin (HbA1c) decreased in the intervention group
and increased in the control group, but the difference
was not significantly different. Extending the study and
offering the intervention to all study practices, alongside
exploring clinical, as well as sociocultural, economic and
genetic variables, provides an opportunity to determine if
there are clinically relevant differences among those with
pre-diabetes who regress to normoglycaemia, who have
2

persistent pre-diabetes and who progress to T2DM. It is
anticipated that these prospectively collected data will
contribute to limited international data on sociocultural
factors that may be associated with regression from pre-
diabetes to normoglycaemia,45 and to clinical decision-
making risk assessments in the primary care setting.21 49
The primary aim of this study is (1) to determine if
there are clinically relevant differences among those with
pre-diabetes who regress to normoglycaemia, those who
have persistent pre-diabetes and those who progress to
T2DM at 6 months following participation in a structured
primary care nurse-delivered pre-diabetes dietary intervention in the primary care setting. The secondary aims
are (2) to quantify the reduction in incident T2DM at
2 years in participants who regressed to normoglycaemia
at 6 months compared with the other participants; (3) to
qualitatively explore and examine barriers, challenges
and facilitators of clinically meaningful lifestyle changes
between those who regress to normoglycaemia and those
who do not; (4) to explore whether a T2DM genetic risk
score of common genetic variants might influence regression to normoglycaemia at 2 years in a sub-sample, (5) to
describe changes in HR-QoL at 2 years and (6) to estimate the potential cost savings to the health sector associated with a reduction in T2DM.

Methods and analysis
This extension of the PIP pilot study is a mixed-method
prospective cohort study with pre-intervention and post-
intervention measures and a qualitative study.50 51
NZ context
In NZ, among adults aged 15 years and over, the prevalence
of diabetes is 7.0% and the prevalence of pre-diabetes is
25.5%.7 Māori, the indigenous people of NZ, and Pacific
people have higher rates than the NZ European and
Other ethnic group, with diabetes rates of 9.8%, 15.4%
and 6.1%, respectively, and pre-diabetes rates of 30.4%,
29.8% and 24.6%, respectively.7 Screening for diabetes
and pre-diabetes is recommended as part of cardiovascular risk assessment.52 For those with no symptoms and
no known risk factors, screening is recommended from
45 years for men and 55 years for women, with Māori,
Pacific, Indo-Asian peoples, and those with known cardiovascular risk factors or at high risk of developing diabetes
to be screened 10 years earlier, or even younger if there is
particular clinical concern regarding unfavourable risk
factors.52
Study setting
The study will be conducted in general practices in the
urban zones of two neighbouring provincial cities (Napier
and Hastings) in the Hawke’s Bay region, NZ. Napier
had a population of 57 240 (18.2% Māori) and Hastings District had a population of 73 245 (23.0% Māori)
in 2013.53 Māori comprise 15% of the NZ population.54
The general practices will be members of the Health
Coppell K, et al. BMJ Open 2019;9:e033358. doi:10.1136/bmjopen-2019-033358
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Hawke’s Bay Primary Health Organisation (PHO). PHOs
are not-
for-
profit organisations that provide primary
health services either directly or through their provider
members. Health Hawke’s Bay is the only PHO in the
study region.
Patient and public involvement
The PIP was designed in collaboration with the Health
Hawke’s Bay PHO.48 The intervention was first pre-tested
with members of the public, then primary care nurses
reviewed and contributed to the implementation and
research protocols at a meeting. The process evaluation
by an independent researcher48 enabled views about the
intervention and its implementation from patient participants, participating nurses and Health Hawke’s Bay PHO
staff involved in the design and implementation to be
incorporated into the planning of this study. Results of
the pilot study and process evaluation were presented and
discussed at a forum to which all participants (patients
and professionals) were invited.
Participant eligibility
General practices who use the Medtech patient management system and employ primary care nurses will
be invited to participate in the study. The reason for
including general practices using Medtech is that this is
the dominant patient management system in Hawke’s
Bay, and study data collection systems had been modified
for Medtech only in the pilot study. The demographic
description of practice populations will be reviewed to
ensure that patients with different sociocultural backgrounds are offered the opportunity to participate.
Adults aged 18–69 years with pre-diabetes (defined as
HbA1c 41–49 mmol/mol according to the NZ diagnostic
criteria)52 and a body mass index (BMI) ≥25 kg/m2 will be
included. Pre-diabetes will have been diagnosed following
screening (at the time of a recommended cardiovascular risk assessment or because they are deemed to be
at risk).52 We set a lower age limit of 18 years to reflect
the high prevalence of pre-diabetes in young adults in
NZ, particularly in high-
risk ethnic groups including
indigenous Māori and Pacific.7 Those with a history of
diabetes, prescribed metformin, unable to communicate
in English, with a terminal illness or planning to move
from the area during the first 6 months of the study and
women pregnant at the time of study enrolment will be
excluded.
Identification of potential participants and recruitment
General practice patient management systems will be used
to identify potential eligible participants. Queries will be
conducted using the HbA1c, BMI, age and metformin
status criteria to generate lists of potential participants.
The queries will not be time-constricted. Primary care
nurses will review these lists to check eligibility status
including co-morbidities, current medications, confirmation of English-speaking ability and pregnancy status. The
lists will be generated in no particular order.
Coppell K, et al. BMJ Open 2019;9:e033358. doi:10.1136/bmjopen-2019-033358

Potential participants will be recruited sequentially
according to the random lists generated, in order to
minimise selection bias. The research nurse will check
these lists regularly to assess who has been invited, who
has declined and who is yet to be invited. A letter inviting
participation and information about the study will be
sent to potential participants in blocks to manage nurse’s
workload. Potential participants will be contacted by their
primary care nurse 5–7 days later to determine participation status and to make a baseline study appointment
for those choosing to participate. For those who decline
to participate, the nurse will record the reason(s). Those
diagnosed with pre-diabetes after recruitment begins and
those who meet the eligibility criteria will be invited to
participate at the time of their diagnosis.
Intervention
The intervention will be delivered by trained primary
care nurses in the general practice setting. The key
underpinning principle of the intervention is to provide
participants (and their family) with an understanding of
the principles of healthy eating and to deliver consistent
evidence-based dietary messages, so they are empowered
to make good dietary choices; that is, the dietary advice
will not be prescriptive. This pragmatic intervention
package has six components48:
Health Professional Training and Support
Primary care nurses will undertake an intensive 3–4 hour
theoretical and practical training course. The course
content will include the rationale for the study, key nutritional concepts, dietary assessment in the primary care
setting (using Starting the Conversation (STC)55 modified for the NZ context),48 healthy conversations and goal
setting. The nurses will be instructed how to use the PIP
study-structured dietary tool,48 and about the necessary
research processes (informed consent and data collection). They will also be instructed on standard practices
for measuring anthropometry and blood pressure. The
course will be delivered by study investigators and a local
dietitian. A training manual will provide reference material for both primary care nurses and participants, as well
as research protocols. A half-day update course will be
run at 6 months.
The local dietitian will be available by email and phone
to answer any queries or discuss specific clinical cases. The
dietitian will also arrange monthly clinical case review
meetings for 6 months at each practice. Both the primary
care nurses and dietitian found that dietitian’s support
and guidance was only required for up to 6 months in the
pilot study.48 A research nurse will also visit participating
practices to provide support and advice, as needed, to
maximise intervention fidelity.
Individualised dietary assessment, goal setting and dietary advice
sessions
The intervention goal is a 10% wt loss over 6 months.
After providing informed written consent, participants
3
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will be offered an initial 30 min individualised dietary
session with their primary care nurse. They will be encouraged to bring family to the session. A brief structured
dietary assessment will be undertaken. STC:Diet, a validated eight-item simplified food frequency instrument
designed for use in primary care and health-promotion
settings, will be used.55 STC:Diet was minimally modified,
with permission, for the NZ context. Specifically, the
word ‘sodas’ was changed to ‘soft drinks’, and a traffic
light system was added to indicate healthy, not-so healthy
and unhealthy dietary habits. The nurse will review the
STC:Diet responses; ask additional dietary prompt questions; seek additional contextual information, such as
household membership and budget, who purchases
household foods and specific dietary requirements/
choices such as vegetarianism and take anthropometric
measures (height, weight and waist circumference) using
calibrated equipment. The additional questions are
called the Detailed Dietary Assessment (DDA). A 10% wt
loss goal over 6 months will be calculated. Responses to
the STC:Diet and DDA will inform three dietary goals
negotiated with the participant, and individualised
dietary advice. Participants will be given the standard
‘Be Active Every Day’ pamphlet, which advises 30 min
of physical activity of moderate intensity on most, if not
all, days of the week.56 Follow-up intervention appointments will be arranged at 2–3 weeks, 6 weeks, 3 months,
4 months and 6 months, then 3-monthly appointments
for a ‘weigh-in’ and provision of ongoing brief targeted
dietary advice and support for 18 months. Intervention
appointments at 6 weeks and 4 months were added,
following feedback from both participants and nurses in
the feasibility study.48 All study appointments will be at
no cost to the participant.
Key messages and consistent opportunistic reminders
Each participant’s three dietary goals will be recorded in
the practice patient management system. These goals and
accompanying clinical notes will facilitate opportunistic
targeted advice and guidance by GPs, thus reinforcing
dietary advice and support provided by the nurses.
The goals will be reviewed and updated accordingly at
follow-up nurse appointments.
Nutritionally supportive primary care environment
Prior to the beginning of this study, each intervention practice will be visited to discuss ways to enhance
dietary messages provided by nurses. Specifically, the
dietary information provided in pamphlets, magazines
and posters in the waiting rooms will be reviewed and
updated, if necessary, so dietary messages are appropriate
and consistent. Provision of magazines that support reputable dietary messages and active living, hobbies and
sports and posters promoting fruit and vegetables, such
as those offered by Vegetables.co.nz (www.vegetables.co.
nz), will be encouraged.
4

Community-based group education for participants and their family
At the 2–3 week intervention appointment, nurses will
refer participants to the Kia Ora programme, a community group nutrition education course consisting of
six weekly sessions of 2.5 hours. The Kia Ora programme
is an approved Stanford chronic disease self-management
programme.57 58 The education sessions will be delivered
by lay trainers, and topics will include healthy eating,
label reading, problem solving and making action plans.
Written patient resources
Readily available patient resources will be utilised. The
key resource will be the Diabetes New Zealand booklet,
Diabetes and healthy food choices,59 a clearly presented and
easily understood source of dietary information. The
booklet was used successfully in the LOADD study,60 and
the PIP pilot study.48
Data collection
Data will be collected as part of the intervention appointments with primary care nurses, as was done in the pilot
study.48 Study data collection forms have been incorporated into the Medtech patient management system.
Additional data will be collected by a research nurse at
separate study-specific visits. Recruitment began August
2017, and it is expected that data collection will be
completed December 2021. The type and frequency of
measurements are shown in table 1. These include:
Routine clinical data
Clinical data will be collected by primary care nurses.
These data will include demographics, medical history,
family history, social history, brief dietary assessment,
height, weight, waist circumference, blood pressure and
bloods (HbA1c, total cholesterol, high-density lipoprotein cholesterol, triglycerides, liver enzymes (alanine
aminotransferase, aspartate aminotransferase and
gamma-glutamyl transferase) and urate. Known data such
as date of birth and ethnicity will pre-populate the study
data collection sheets and additional pre-diabetes clinical
management data (eg, brief dietary assessment details)
will be added by the primary care nurses during the intervention consultations.
Additional study-specific quantitative data
A research nurse will administer a questionnaire and
arrange for a fasting blood sample to be taken. The questions will explore areas known to influence pre-diabetes
lifestyle management. Data will be collected on self-
monitoring activities (self-weighing at home, food diaries
and self-initiated attendance at support groups), social
support systems,61 62 sleep patterns,63 stages and processes
in weight management,64 65 physical activity (the International Physical Activity Questionnaire (IPAQ) long)66 and
HR-QoL using the EQ-5D.67 68 The additional non-routine
blood tests will include fasting insulin and fasting glucose
(to enable calculation of homeostatic model assessment
(HOMA)69 and the McAuley Index,70 both measures
Coppell K, et al. BMJ Open 2019;9:e033358. doi:10.1136/bmjopen-2019-033358

BMJ Open: first published as 10.1136/bmjopen-2019-033358 on 9 December 2019. Downloaded from http://bmjopen.bmj.com/ on January 30, 2020 at Serials Aquisitions Edith Cowan
University Library. Protected by copyright.

Open access

Genetic testing
The genomes from participants who, in addition to the
main study, provide consent to genetic testing, and are
from the opposite ends of the response spectrum will be
sequenced, with the intention of sequencing genomes
from all consenting participants as the cost of sequencing
reduces. Using genome-
wide single nucleotide polymorphism (SNP) genotyping platforms would not be
adequate as these platforms use common genetic variants
identified in other populations. WGS is the only practical
approach as it will allow identification of uncommon
(including Māori-specific) variants predicted to have a
strong functional effect in the suite of genes to be analysed
for a burden of functional variation. WGS also allows evaluation of regulatory variants which would not be possible
using an exome sequencing approach. Sequencing will
be done at 30-fold coverage.
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Sample size calculations
The sample size calculation used information from the
Voglibose study.21 71 It was assumed that 25% of those with
pre-diabetes at baseline will regress to normoglycaemia
at 6 months. Assuming 5% loss to follow-up at 6 months,
a sample of 400 people with pre-diabetes will provide
80% power to detect factors associated with regression at
6 months with relative risks for regression of 2.2 or higher,
for any two groups each comprising between 20% and
80% of the sample using a two-sided test at p<0.05 level
of significance.

 

Includes Social Support Systems,61 62 Sleep Quality,63 Stages and Processes in Weight Management,64 65 IPAQ (long),66 EQ-5D-5L.67 68
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; HbA1c, glycated haemoglobin; IPAQ, International Physical Activity Questionnaire.
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x

x

 

x

 

x

x

 

21 months 24 months

of insulin resistance), and whole genome sequencing
(WGS) in a sub-sample.

Outcome measures
The primary outcome measures will be HbA1c (mmol/
mol) and weight (kg). Other outcome measures will
include waist circumference, BMI, social support score,
behavioural change score and EQ-5D scores.

Planned statistical analysis
STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology)72 and TRIPOD (Transparent
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis)73 reporting standards
will be used. Descriptive statistics will be provided for all
measures of interest, as appropriate. For inferential analyses, all results will be reported showing effect sizes, 95%
CIs and p values. Two-
sided p<0.05 will be considered
statistically significant. Analyses will be conducted using R
V.3.5.1 and Stata V.15.1 (or later versions).
Poisson regression with robust standard errors and
clustered by practice (using Froot’s extension to Huber–
White estimators74) will be used to identify predictors of
regression to normoglycaemia and progression to T2DM
at 6 months. Similar models will be used to examine
risk factors for developing T2DM at 2 years. Exploratory
modelling will use Markov models to identify variables
associated with transitions between the three glycaemic
states of interest, defined according to the NZ definitions:
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normoglycaemia (HbA1c<41 mmol/mol), pre-
diabetes
(41 mmol/mol≥HbA1 c ≤ 49 mmol/mol) and diabetes
(HbA1c>49 mmol/mol).52 Providing the number of transitions between each pair of states is sufficient, multistate
models will initially be used to describe transition probabilities between these states over all measurement times
(all three transitions are possible) with an absorbing state
of death also reachable from any of these three states.
Factors associated with transitions between these three
glycaemic states (but not between these states and death)
are the focus of this study and these prognostic variables
will be used to construct models of the relative risks for
transitions between each pair of stages. Initially, these
factors will be evaluated independently and Hosmer–Lemeshow’s criteria for logistic regression of unadjusted
p<0.25 will be used to identify candidate predictors for
further (adjusted) modelling.75 The number of potential
predictors included in adjusted models will be limited by
the number of transitions providing data for parameter
estimates. Peduzzi et al’s heuristic for logistic regression
of 10 events (and 10 non-events) per parameter estimated
will be used to determine the maximum model complexity
when identifying predictors for further examination.76 If
more factors are identified than can be modelled using
the Hosmer-Lemeshow screening heuristic, selection will
be based on favouring modifiable factors which could
be used to inform interventions over non-
modifiable
factors. Similarly, where multiple predictors are identified
that are highly correlated, only one will be retained for
further modelling. If data allow estimation of the necessary number of parameters, time-dependent transition
probabilities will be estimated in similar ways.
A genetic risk score will be compiled from common variants identified as T2DM-associated from a NZ genome-
wide association study of T2DM currently in progress.
The genetic risk score will be tested for association with
the outcomes of the intervention in the sub-sample of
participants with genetic information.

Economic analysis
Using the EQ-
5D scores, the number and percentage
of participants reporting each level of problem on each
dimension of the EQ-5D will be described by age, gender
and ethnicity, and compared across time and groups (ie,
those who regress to normoglycaemia, those who have
persistent pre-diabetes and those who progress to T2DM).
Participants’ self-reported health status as measured on
the EQ Visual Analogue Scale will also be reported. An
estimate of potential cost savings (acknowledging that
any change in glycaemic status cannot be attributed to
the programme with certainty) will be calculated from a
funder’s perspective using average cost estimates and the
expected rate of progression to T2DM.

Qualitative component
Inclusion of qualitative approaches in the design and
reporting of evaluations of complex health interventions
is relatively uncommon and rarely reported, although
qualitative components offer opportunities to enhance
the interpretation of the quantitative outcome data.77–79
The qualitative component of this study will provide
important insight into the psychosociocultural factors
that influence lifestyle change in relation to regression
to normoglycaemia. It will specifically explore the experience of being diagnosed with pre-
diabetes and how
both those who regress to normoglycaemia at 6 months
and those who do not describe the process in relation to
barriers to and facilitators of lifestyle changes.
A purposive sample of 60 participants who have
completed the 6-month intervention will be sought (30
people who regressed to normoglycaemia and 30 people
who did not). The sample will be stratified to include equal
numbers of participants by gender and half of the sample

Ethics and dissemination
Local consultation with Māori was facilitated via Health
Hawke’s Bay’s Operational Māori Advisor and was undertaken at the outset of study planning, particularly in relation to the genetic studies. The study was endorsed by the
Priority Population Committee of the regional primary
health organisation, Health Hawke’s Bay. This committee
is tasked with ensuring programmes contribute to equitable access and health gains for Māori, Pacific and other
populations living in high deprivation areas (NZ deprivation score 9–10).84 Study author, DT-L (Māori public
health physician), performed an advisory role across all
appropriate planning components of the study and will
be in-field cultural advisor across the project, in particular
for the research nurse and the qualitative researcher. The
study was also endorsed by the University of Otago Ngāi
Tahu Research Consultation Committee.
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will comprise indigenous Māori to ensure that a meaningful level of analysis can be undertaken. Participants
will be selected from those who agreed to participate in
further research when first recruited into the main study.
Those purposively selected will be contacted shortly after
completion of the 6-month measures to arrange a face-to-
face interview if willing to participate in this part of the
study. Written consent will be obtained immediately prior
to this interview, which will last approximately 60 min.
The interviewer (SA), who has, with co-author (DT-L),
worked and published extensively in projects where the
cross-cultural context is central, will ensure cultural safety
throughout the interview process with Māori and Pacific
participants.80 81With permission, all interviews will be
audio recorded and transcribed.
Analysis will be completed by a sub-
team (SA, LW,
DT-L and KC) using thematic analysis.82 This will involve
multiple reading of transcriptions followed by the development and description of a priori and emergent themes
and concepts. Further analysis will explore interconnections between themes. The thematic findings will also be
triangulated with the quantitative data to assist interpretation of results and provide descriptive context.83
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Further consultation was undertaken specifically with
respect to taking blood for genetic analysis. Families will
be interested in learning if there is a genetic link with a
higher risk of T2DM. The most obvious outcome would
include a more responsive health system with early detection, destigmatisation, early ‘no blame’ intervention and
prevention programmes for family who are at risk of
developing T2DM. As part of the study, participants will
be given a choice on consenting as to the disposal of body
fluids/parts as per the University of Otago’s and Hawke’s
Bay District Health Board’s Policies and Procedures.
The main study results will be first presented to participating GPs and participating patients. The results of
the study will be written and published in peer-reviewed
journals and presented at relevant conferences. A written
summary of the results will also be distributed to participants, participating GPs, and published on Health
Hawke’s Bay website for their members.
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